Gianluca Iacobellis
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1003123415
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,830 of the $4,972 with a category attached, or 97.1%. Novo Nordisk accounts for 97.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $2,790, more than ten times the $63 reported in 2019.
Across 11 payments — averaging $451.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$5K
- Osprey Medical Inc$49
- AstraZeneca$47
- Johnson & Johnson$18
- Merck$16
- Lilly USA, LLC$12
Across 12 payments — averaging $28,440 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$265K
- AstraZeneca$77K
What the payments were for
- Consulting fees$4,83097%
- Food & beverage$1303%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $4,830 |
| Osprey Medical Inc | 1 | $49 |
| AstraZeneca | 3 | $47 |
| Johnson & Johnson | 1 | $18 |
| Merck | 1 | $16 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$2,040
How this compares
$4,972 in reported general payments places this provider in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 352 | $552,651 |
| MounjaroTirzepatide | 346 | $520,361 |
| JardianceEmpagliflozin | 378 | $506,358 |
| TrulicityDulaglutide | 214 | $330,916 |
| Tresiba Flextouch U-100Insulin Degludec | 203 | $141,357 |
| RybelsusSemaglutide | 49 | $101,255 |
| FarxigaDapagliflozin Propanediol | 80 | $84,070 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $49,759 |
| JanuviaSitagliptin Phosphate | 37 | $46,675 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 48 | $45,718 |
| SynjardyEmpagliflozin/Metformin Hcl | 28 | $34,046 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $31,924 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $28,927 |
| TradjentaLinagliptin | 23 | $26,775 |
| Novolog FlexpenInsulin Aspart | 127 | $26,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $12 | $852,834578 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $4,830 | $657,786422 claims |
| AstraZenecaFarxiga | $47 | $84,07080 claims |
| MerckJanuvia, Janumet | $16 | $78,60072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Miami
- Jay SkylerMiami$2.2M
- Eugenio Angueira-SerranoMiami$603K
- Rodolfo GalindoMiami$229K
- Camillo RicordiMiami$128K
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.